Conventional medical therapy, with either a combination of phosphate and calcitriol, or burosumab, an FGF23‐blocking monoclonal antibody, effectively treats the consequences of hypophosphatemia, but does not target the tumor directly.(8, 9) With current medical treatment options, there remains a risk of continued tumor growth or tumor metastasis.(10, 11). This evidence concerns the gene FGF23 and hypophosphatemia.